INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Bramitob® (tobramycin)
Key information

Bramitob (tobramycin) is for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients with cystic fibrosis aged 6 years and older.1

In a multi-centre, double-blind, placebo-controlled study (300 mg/4ml Bramitob vs placebo, n=247):

  • Bramitob resulted in significant improvements in FEV1 % predicted (p<0.001) at weeks 2, 4, 20 and 24, FVC (p=0.022) and FEF25-75% (p=0.001) vs. placebo2
  • Reduced hospitalisations by 50% (relative risk reduction; absolute risk reduction=18.3%) vs. placebo (absolute risk=18.6% vs 36.9%) and reduces need for other antipseudomonal antibiotics2

Favourable tolerability profile and maintained short-term clinical benefit similar to TOBI®3

Twice daily dosing, 15 minutes, every other month1

 

 

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF25-75%, forced expiratory flow at 25-75%


1. Bramitob® Summary of Product Characteristics. Available online at https://www.medicines.org.uk/emc/medicine/21427. Accessed March 2018.
2. Chuchalin A, et al. Pediatr Drugs. 2007; 9 Suppl. 1:21-31.
3. Mazurek H, et al. Pediatr Pulmonol. 2014; 49:1076-89.